DGX News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$25.93B

Volume

595.93K

Next Earnings

October 22nd

Mkt Cap

$26.40B

Volume

595.93K

Next Earnings

October 22nd

Chart Financials Earnings News About Dividends Insider Filings

Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusZacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.Zacks Investment Research · Oct 5, 2026

Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product SegmentsThe global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.GlobeNewswire Inc. · Sep 24, 2026

Is This the Right Time to Add DGX Stock to Your Portfolio?Quest Diagnostics (DGX) is experiencing growth across physician, hospital, and consumer channels, driven by customer wins and an expanding advanced diagnostics portfolio delivering double-digit growth. The company targets 3% annual cost savings through AI and automation initiatives. However, reimbursement uncertainty, cost pressures, and elevated debt of $5.63 billion remain concerns that could impact margins and financial flexibility.Zacks Investment Research · Sep 22, 2026

Beat the Market Like Zacks: PBF, Palantir, Adobe in FocusZacks Investment Research showcased strong performance across its various stock rating systems and portfolios. PBF Energy and Delek US surged following Zacks Rank #1 upgrades, while the Zacks #1 Rank portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date. Notable performers included Palantir (up 38.3% over 12 weeks), Adobe (up 27.6%), Thermo Fisher (up 40.2%), and Monolithic Power Systems (up 30.1% since January 5, 2026). The article emphasizes Zacks' track record of outperforming the market since 1988.Zacks Investment Research · Sep 21, 2026

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?Quest Diagnostics (DGX) has reached a new 52-week high of $248.65, gaining 42.4% year-to-date with a strong track record of beating earnings estimates. The stock carries a Zacks Rank #2 (Buy) with a B VGM Score, though it trades at a premium valuation of 22.2X current fiscal year EPS versus the industry average of 20.4X. The Medical - Outpatient and Home Healthcare industry is in the top 18% of all industries, providing positive tailwinds for the sector.Zacks Investment Research · Sep 16, 2026

Quest Diagnostics CEO Sells 10,000 Shares for $2.4 MillionQuest Diagnostics CEO J. E. Davis sold 10,000 shares worth $2.4 million on September 1, 2026, under a pre-planned Rule 10b5-1 trading arrangement. The sale represents 8% of his direct holdings, leaving him with $28.9 million in company stock. Analysts view this as a routine portfolio adjustment rather than a sign of concern about the company's fundamentals.The Motley Fool · Sep 8, 2026

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in FocusZacks highlights strong stock performance from its various rating systems and portfolios. Oportun Financial gained 31% after a Zacks Rank upgrade, Uranium Royalty advanced 67.6% following an Outperform recommendation, and Amgen returned 25.1% over 12 weeks. The article discusses economic conditions marked by geopolitical tensions, rising energy costs, and resilient but cooling labor markets, while showcasing the historical outperformance of Zacks' investment methodologies.Zacks Investment Research · Sep 8, 2026

Global Pathology Services Market to Reach $307.9 Billion by 2030, Driven by Rising Cancer Incidence and AI-Enabled Diagnostic InnovationThe global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.GlobeNewswire Inc. · Aug 31, 2026

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsightThe global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.GlobeNewswire Inc. · Aug 27, 2026

Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.GlobeNewswire Inc. · Jul 22, 2026

DGXQuest Diagnostics Inc.

DGX

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any DGX yet.

Related Tickers

Earnings

Dividends

Last · Oct 6Quarterly

Amount$0.86

Yield1.44%

Annual$3.38

Mkt Cap

$25.93B

Volume

595.93K

Next Earnings

October 22nd